Cargando…

Effects of Alemtuzumab on (Auto)antigen-Specific Immune Responses

Alemtuzumab (anti-CD52 mAb) leads to a long-lasting disease activity suppression in patients with relapsing forms of multiple sclerosis (MS). In this study, we examined the change of the immune cell repertoire and the cellular reactivity after treatment with alemtuzumab. We analyzed the number of IF...

Descripción completa

Detalles Bibliográficos
Autores principales: Hilger, Clara, Riedhammer, Christine, Orsó, Evelyn, Weissert, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578345/
https://www.ncbi.nlm.nih.gov/pubmed/33133074
http://dx.doi.org/10.3389/fimmu.2020.563645